Publications by authors named "Kanayama Y"

Article Synopsis
  • - The study evaluated the effectiveness of switching osteoporosis treatments between two bone formation-promoting agents, teriparatide and romosozumab, in a cohort of 94 patients over 12 months.
  • - The results showed that patients transitioning from teriparatide to romosozumab (T2R group) had significant increases in bone mineral density (BMD) across various sites, while those switching from romosozumab to teriparatide (R2T group) experienced no significant change.
  • - The findings suggest that switching from teriparatide to romosozumab leads to better outcomes for increasing BMD compared to the reverse sequence, highlighting a more effective treatment strategy for osteoporosis.
View Article and Find Full Text PDF

Aim: Since the development of tremelimumab plus durvalumab (Dur/Tre) for unresectable hepatocellular carcinoma (uHCC), it has been used as not only an initial but also later line treatment in clinical practice. This study aimed to elucidate clinical prognostic factors for progression-free survival (PFS) in Dur/Tre treatment cases.

Methods: Enrolled were 183 uHCC patients treated with Dur/Tre from 2023 to May 2024 (median age, 74 years; male patients, 152; Child-Pugh class A:B, 150:33; Barcelona Clinic Liver Cancer stage B:C, 59:124; initial line use, 64).

View Article and Find Full Text PDF

Aim: The objective of this study was to compare the clinical effectiveness of baricitinib and abatacept in patients with rheumatoid arthritis (RA).

Methods: This study included 274 patients treated with abatacept and 241 treated with baricitinib who were followed for >52 weeks. Potential treatment selection bias was addressed by using inverse probability of treatment weighting.

View Article and Find Full Text PDF

We aimed to investigate the efficacy of romosozumab treatment compared with that of denosumab in especially male osteoporosis patients. This retrospective cohort study included 174 Japanese male patients receiving either denosumab or romosozumab for 12 months. Propensity score matching extracted 50 patients per treatment group for standardization of group characteristics.

View Article and Find Full Text PDF
Article Synopsis
  • Durvalumab plus tremelimumab (Durva/Treme) is the first-line immunotherapy option for patients with unresectable hepatocellular carcinoma (HCC), with a reported objective response (OR) rate of 15.5%.
  • The study involved 110 patients and aimed to identify whether changes in tumor markers, specifically alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP), could serve as predictive biomarkers for treatment response, using data collected both before and four weeks after treatment.
  • It was found that higher baseline AFP levels (≥ 400 ng/mL) significantly correlated with better OR rates, and a ≥10% reduction in AFP or DCP
View Article and Find Full Text PDF
Article Synopsis
  • - This study investigates what factors predict conversion therapy success in patients with unresectable hepatocellular carcinoma (uHCC) and compares the survival outcomes of those who underwent conversion therapy to those with partial or complete responses after treatment with atezolizumab and bevacizumab.
  • - Out of 946 uHCC patients studied, only 43 (4.5%) received conversion therapy, with a higher overall response rate in this group (65.1%) compared to those who did not undergo conversion therapy (23.7%), indicating a statistically significant difference.
  • - Factors such as earlier BCLC stage, lack of macrovascular invasion or extrahepatic spread, and low neutrophil to lymphocyte ratio were found
View Article and Find Full Text PDF
Article Synopsis
  • An 80-year-old woman with chronic hepatitis C developed rapidly growing lymph node metastasis of hepatocellular carcinoma (HCC) after initial treatment.
  • Given the operable but invasive nature of the tumor, systemic chemotherapy with atezolizumab and bevacizumab was initiated to prepare for less invasive surgery.
  • After four cycles of therapy, the metastasis significantly decreased, leading to successful lymph node dissection with no remaining metastatic lesions, marking a breakthrough in treating HCC lymph node metastasis.
View Article and Find Full Text PDF

The coat protein (CP) of the cucumber mosaic virus (CMV) yellow strain [CMV(Y)], but not the CMV B2 strain [CMV(B2)], serves as an avirulence determinant against the NB-LRR class RCY1 of Arabidopsis thaliana. To investigate the avirulence function, a series of binary vectors were constructed by partially exchanging the CP coding sequence between CMV(Y) and CMV(B2) or introducing nucleotide substitutions. These vectors were transiently expressed in Nicotiana benthamiana leaves transformed with modified RCY1 cDNA.

View Article and Find Full Text PDF

Objectives: The present study aimed to investigate the effectiveness of treatment with romosozumab for 1 year and association between bone turnover markers and changes in bone mineral density (BMD) in patients with postmenopausal osteoporosis.

Methods: Participants were 53 treatment-naïve postmenopausal osteoporosis patients. Correlations of per cent changes (Δ) in lumbar (L) and total hip (TH) BMD 12 months after initiating romosozumab with baseline demographic factors and parameters of N-terminal propeptide of Type 1 collagen (P1NP) and tartrate-resistant acid phosphatase-5b at baseline and Months 1, 3, and 6 were assessed.

View Article and Find Full Text PDF

Background: Vitiligo presents with varying clinical features based on the type and location. Treatment tends to be more effective on the face, neck, trunk, and mid-extremities, while the lips and distal extremities may be more resistant. Vitiligo in frequently exposed areas such as the face, arms, legs, and hands is typically associated with a lower Dermatology Life Quality Index.

View Article and Find Full Text PDF

Objectives: We investigated the effect of belimumab (BEL) on achieving low disease activity (LDA) and remission as an additive molecular-targeting agent to standard of care (SoC) in patients with systemic lupus erythematosus (SLE).

Methods: Clinical information was retrospectively collected from patients with SLE who received BEL additive to SoC (BEL + SoC), and from patients treated with SoC alone as a control arm. Disease activity was measured by SLE-disease activity score (SLE-DAS).

View Article and Find Full Text PDF

Studies evaluating xanthine oxidoreductase (XOR) activities in comprehensive liver diseases are scarce, and different etiologies have previously been combined in groups for comparison. To accurately evaluate XOR activities in liver diseases, the plasma XOR activities in etiology-based comprehensive liver diseases were measured using a novel, sensitive, and accurate assay that is a combination of liquid chromatography and triple quadrupole mass spectrometry to detect [C, N]uric acid using [C, N]xanthine as a substrate. We also mainly evaluated the association between the plasma XOR activities and parameters of liver tests, purine metabolism-associated markers, oxidative stress markers, and an inflammation marker.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the role of cerebrospinal fluid (CSF) interleukin-6 (IL-6) and blood-brain barrier (BBB) permeability in patients with systemic lupus erythematosus (SLE) who exhibit neuropsychiatric symptoms resembling neuromyelitis optica spectrum disorder (NMOSD).
  • - Researchers analyzed data from twelve SLE patients with brainstem and spinal cord lesions, finding that treatment significantly decreased CSF IL-6 levels and identified correlations between IL-6 and specific autoantibodies such as anti-dsDNA and anti-Smith.
  • - The findings suggest that CSF IL-6 could serve as a potential biomarker for monitoring neurological symptoms in S
View Article and Find Full Text PDF

Background And Study Aims: The long-term comprehensive prognosis of chronic hepatitis C after direct-acting antiviral (DAA) therapy is unclear. This study aimed to investigate the prognosis and incidence of immunological and oncological complications after DAA therapy.

Patients And Methods: The study included a total of 1461 patients who received DAA therapy in our university hospital and affiliated hospitals between September 3, 2014 and September 30, 2018.

View Article and Find Full Text PDF

Background: Postoperative protocols after surgical treatment of calcaneal fracture have not been standardized to date. There are only a few reports on the efficacy of heel-unloading orthoses (HUOs; Mars shoe, Graffin orthosis), and thier efficacy is uncertain.

Objectives: The purpose of this study was to compare postoperative radiologic and clinical outcomes in patients with calcaneal fractures who used Graffin orthosis.

View Article and Find Full Text PDF

Light quality affects plant growth and the functional component accumulation of fruits. However, there is little knowledge of the effects of light quality based on multiomics profiles. This study combined transcriptomic, ionomic, and metabolomic analyses to elucidate the effects of light quality on metabolism and gene expression in tomato fruit.

View Article and Find Full Text PDF

Objectives: Patients with rheumatoid arthritis (RA) usually switch to a second biological disease-modifying antirheumatic drugs (bDMARDs) when the first has proven to be ineffective, although some may discontinue bDMARDs treatment altogether. We investigated the total rate of bDMARDs retention and the risk of bDMARDs discontinuation in patients with RA.

Methods: The study included 564 patients with RA who started bDMARDs treatment before 2008 (<65 years old, n = 413; ≥65, n = 151).

View Article and Find Full Text PDF

We experienced a case of bilateral shoulder bursitis with gas images in a rheumatoid arthritis (RA) patient. A 60-year-old man with RA had been treated with weekly methotrexate 10 mg and daily prednisolone (PSL) 10 mg for 7 months. Generalized pain, especially in the bilateral shoulder joints, developed and exacerbated daily with increased C-reactive protein (CRP) level.

View Article and Find Full Text PDF

Three Japanese adolescents with chronic hepatitis C were treated by direct-acting antivirals (DAAs). No adverse events or laboratory abnormalities were observed during and after DAA therapy, and a sustained virological response was achieved in all cases. The emotional functioning of the patients and their mothers were improved after DAA therapy.

View Article and Find Full Text PDF

We examined 171 patients with novel coronavirus disease 2019 (COVID-19) with liver injury in the respiratory failure groups and the nonrespiratory failure groups and investigated 41 patients with moderate II COVID-19 with respiratory failure who received dexamethasone (Dex) monotherapy in the liver injury group and the nonliver injury group at the time before treatment. The respiratory failure group had 64% more liver damage than the nonrespiratory failure group, was older, had more men, and had significantly more complications from lifestyle-related diseases such as hypertension and diabetes. Obesity was more common in the liver injury group prior to Dex monotherapy, and the liver CT value was significantly lower than in the nonliver injury group.

View Article and Find Full Text PDF

The insufficient energy and spatial resolutions of radionuclide imaging with conventional scintillation detectors restrict the visualization of multiple radionuclides and of microstructures in tissue. Here we report the development and performance of an imaging system equipped with a cadmium telluride diode detector that achieves an energy resolution of 1.7% at 140 keV and a spatial resolution of 250 μm.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigated how well biological disease-modifying antirheumatic drugs (bDMARDs) work when taken with tacrolimus (TAC) in patients with rheumatoid arthritis, focusing on safety and effectiveness.
  • - A total of 2,792 patients were included, with groups receiving either TAC, methotrexate (MTX), both, or neither. The main goal was to see how many patients had to stop treatment due to adverse events or loss of effectiveness.
  • - Results showed that patients taking TAC had significantly lower rates of treatment discontinuation due to adverse events and loss of effectiveness compared to those not on TAC, indicating that TAC can be a beneficial addition to bDMARD therapy.
View Article and Find Full Text PDF